GENOCEA BIOSCIENCES, INC. short interest in 2019
In 2019, GENOCEA BIOSCIENCES, INC.'s disclosed short interest ran from 2.24% of shares outstanding on 15 Jan 2019 to 0.37% on 31 Dec 2019, a change of -1.87 percentage points. The year's high was 2.24% on 15 Jan 2019 and its low 0.31% on 13 Dec 2019, averaging 1.17% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.40 days on 31 Jan 2019. Full history: GENOCEA BIOSCIENCES, INC..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022
2019 in figures
- Start of year
- 2.24% (15 Jan 2019)
- End of year
- 0.37% (31 Dec 2019)
- Change
- -1.87 pp
- High
- 2.24% (15 Jan 2019)
- Low
- 0.31% (13 Dec 2019)
- Average
- 1.17%
- Highest days to cover
- 19.40 (31 Jan 2019)
- SEC filings marked
- 8
Every report in 2019
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2019 | 2.24% | 4.40 | |
| 31 Jan 2019 | 2.18% | 19.40 | |
| 15 Feb 2019 | 2.14% | 9.53 | |
| 28 Feb 2019 | 1.83% | 1.21 | 10-K filed, results (8-K) |
| 15 Mar 2019 | 1.56% | 4.01 | |
| 29 Mar 2019 | 1.52% | 5.45 | |
| 15 Apr 2019 | 1.47% | 2.01 | |
| 30 Apr 2019 | 1.22% | 4.62 | 10-Q filed, results (8-K) |
| 15 May 2019 | 1.27% | 4.93 | |
| 31 Jul 2019 | 1.92% | 2.39 | 10-Q filed, results (8-K) |
| 15 Aug 2019 | 1.17% | 2.47 | |
| 30 Aug 2019 | 0.99% | 3.18 | |
| 13 Sep 2019 | 0.74% | 1.00 | |
| 30 Sep 2019 | 0.68% | 1.47 | |
| 15 Oct 2019 | 0.50% | 1.62 | |
| 31 Oct 2019 | 0.49% | 1.27 | 10-Q filed, results (8-K) |
| 15 Nov 2019 | 0.40% | 1.00 | |
| 29 Nov 2019 | 0.41% | 1.00 | |
| 13 Dec 2019 | 0.31% | 1.00 | |
| 31 Dec 2019 | 0.37% | 1.00 |
See also: GENOCEA BIOSCIENCES, INC.'s full history · most shorted US stocks of 2019 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.